A Phase 2 interventional study of Cobimetinib and Atezolizumab in Metastatic Melanoma, sponsored by Hoffmann-La Roche. Completed at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.
Among the 27 studies testing cobimetinib in Melanoma, this one is the 8th largest by enrollment, is one of 5 that started in 2018, is one of 18 in phase 2, and was the 22nd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Ages 19+
N.N. Petrov National Medical Research Center of Oncology · Sites in Russian Federation
Ages 18–85 · Healthy volunteers
Cancer Research UK · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cobimetinib is the treatment under test here. Read study by study →
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 4
First in 2011; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 45 across the 27 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
57 studies in Melanoma by Hoffmann-La Roche: none open now, 4 under way, none of them phase 3. Of 52 finished, 34 (65%) have results posted.
Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 22nd largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 2, and was the 46th registered.
Hoffmann-La Roche’s Melanoma studies by the year they started, since 2004.
1 of the studies testing cobimetinib in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04835805Genentech, Inc.A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing cobimetinib in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 57 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma patients with CNS metastases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease-specific inclusion criteria:
General inclusion criteria:
Exclusion criteria:
Disease-specific exclusion criteria:
For patients assigned to Cohort 2 only: prior immunotherapy in either the adjuvant or metastatic setting is not allowed.
General exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
Drug: Cobimetinib · Drug: Atezolizumab
Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
Drug: Cobimetinib · Drug: Atezolizumab · Drug: Vemurafenib
60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
Also known as: Cotellic
Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1).
Also known as: Tecentriq
Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
Also known as: Zelboraf
Intracranial Objective Response Rate (ORR)
Intracranial ORR is defined as the percentage of participants with either a complete response (CR) or a partial response (PR) in their intracranial disease based on two consecutive assessments \>= 4 weeks apart. Disease status for this endpoint will be determined by an Independent Review Committee (IRC) in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) with modified measurability definition for intracranial lesions (\>= 0.5 cm by MRI) and allowing up to five intracranial target lesions. CR is defined as disappearance of all lesions. PR is defined as \>=30% decrease in tumor burden, in the absence of CR. The primary endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.
Time frame: Baseline up to cut of date (approximately 2.5 years)
Extracranial ORR
Extracranial ORR, defined as the percentage of participants with either a CR or PR in their extracranial disease based on two consecutive assessments \>=4 weeks apart, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to cut of date (approximately 2.5 years)
Overall ORR
Overall ORR, defined as the percentage of participants with either a CR or PR in their overall disease (i.e. including intracranial and extracranial disease) based on two consecutive assessments \>= 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.
Time frame: Baseline up to cut of date (approximately 2.5 years)
Progression-Free Survival (PFS)
Intracranial, extracranial and overall PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to cut of date (approximately 2.5 years)
Duration of Response (DOR)
Intracranial, extracranial and overall DOR, defined as the time from the first occurrence of a documented objective response based on two consecutive assessments ≥ 4 weeks apart to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.
Time frame: Baseline up to cut of date (approximately 2.5 years)
Disease Control Rate (DCR)
Intracranial, extracranial and overall DCR, defined as the percentage of participants with a CR or PR or stable disease (SD) at 16 weeks from study treatment initiation, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD is defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for disease progression. Disease progression is defined as \>=20% increase in tumor burden. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.
Time frame: At 16 weeks
Overall Survival (OS)
OS is defined as the time from study treatment initiation to death from any cause.
Time frame: Baseline up to 4 years, 4 months
Time to Cognitive Symptom Deterioration
Time from study treatment initiation to cognitive symptom deterioration, defined as a change (\>= 10 points on a 0-100 scale) on selected scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BN20) (visual disorder, motor dysfunction, communication deficit, headaches, seizures and drowsiness).
Time frame: Up to 48 months
Time to Symptom and Function Deterioration
Time from study treatment initiation to symptom and function deterioration defined as a change (\>= 10 points on a 0-100 scale) in fatigue, physical functioning, cognitive functioning, or role functioning as measured by the Fatigue, Physical, Cognitive, Role Functioning scales of the EORTC QLQ-C30.
Time frame: Up to 48 months
Duration of Stable/Improved Health-related Quality of Life (HRQoL) Scores
Duration of Stable/Improved HRQoL scores as assessed through use of the two-item Global Health Status (GHS)/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30.
Time frame: Baseline up to cut of date (approximately 2.5 years)
Percentage of Participants With Adverse Events
The safety profile of Cobimetinib plus Atezolizumab and Cobimetinib plus Atezolizumab plus Vemurafenib is evaluated in terms of occurrence and severity of AEs. Severity will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0)
Time frame: Baseline up to 4 years, 4 months
The study was conducted at 21 centers in 7 countries.
| Milestone | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Started | 15 | 65 |
| Completed | 0 | 0 |
| Not completed | 15 | 65 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Study terminated by sponsor | 1 | 13 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Withdrawal of consent | 0 | 1 |
| Withdrew: Death | 11 | 47 |
| Withdrew: Progressive disease | 0 | 2 |
Intracranial ORR is defined as the percentage of participants with either a complete response (CR) or a partial response (PR) in their intracranial disease based on two consecutive assessments \>= 4 weeks apart. Disease status for this endpoint will be determined by an Independent Review Committee (IRC) in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) with modified measurability definition for intracranial lesions (\>= 0.5 cm by MRI) and allowing up to five intracranial target lesions. CR is defined as disappearance of all lesions. PR is defined as \>=30% decrease in tumor burden, in the absence of CR. The primary endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.
| Percentage of participants | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|
| Intracranial Objective Response Rate (ORR) | 46.4 (32.99 to 60.26) |
Extracranial ORR, defined as the percentage of participants with either a CR or PR in their extracranial disease based on two consecutive assessments \>=4 weeks apart, as determined by the investigator according to RECIST v1.1.
| Percentage of participants | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Extracranial ORR | 20.0 (4.33 to 48.09) | 56.9 (44.04 to 69.15) |
Overall ORR, defined as the percentage of participants with either a CR or PR in their overall disease (i.e. including intracranial and extracranial disease) based on two consecutive assessments \>= 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.
| Percentage of participants | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Overall ORR | 26.7 (7.79 to 55.10) | 52.3 (39.54 to 64.85) |
Intracranial, extracranial and overall PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
| Months | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Intracranial | 2.17 (1.74 to 7.98) | 5.78 (5.36 to 7.43) |
| Extracranial | 4.21 (1.84 to 12.65) | 10.68 (7.85 to 13.67) |
| Overall | 1.81 (1.71 to 3.71) | 5.49 (5.13 to 7.43) |
Intracranial, extracranial and overall DOR, defined as the time from the first occurrence of a documented objective response based on two consecutive assessments ≥ 4 weeks apart to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.
| Months | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|
| Intracranial | 6.7 (5.6 to 9.5) |
| Extracranial | 11.6 (9.2 to 13.0) |
| Overall | 7.4 (5.5 to 9.5) |
Intracranial, extracranial and overall DCR, defined as the percentage of participants with a CR or PR or stable disease (SD) at 16 weeks from study treatment initiation, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD is defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for disease progression. Disease progression is defined as \>=20% increase in tumor burden. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.
| Percentage of participants | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|
| Intracranial | 50.8 (38.07 to 63.40) |
| Extracranial | 50.8 (38.07 to 63.40) |
| Overall | 50.8 (38.07 to 63.40) |
OS is defined as the time from study treatment initiation to death from any cause.
| Months | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|
| Overall Survival (OS) | 13.40 (10.68 to 16.92) |
Time from study treatment initiation to cognitive symptom deterioration, defined as a change (\>= 10 points on a 0-100 scale) on selected scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BN20) (visual disorder, motor dysfunction, communication deficit, headaches, seizures and drowsiness).
| Months | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Visual Disorder | 3.75 (1.87 to NA) | 2.99 (1.41 to 8.74) |
| Motor Dysfunction | 1.87 (1.08 to 19.84) | 6.70 (3.94 to 13.90) |
| Communication Deficit | 6.44 (2.83 to NA) | 13.90 (6.54 to 21.13) |
| Headaches | NA (1.08 to NA) | 10.84 (5.55 to NA) |
| Seizures | 8.31 (8.31 to NA) | NA (17.74 to NA) |
| Drowsiness | 2.83 (1.08 to NA) | 7.16 (1.94 to NA) |
Time from study treatment initiation to symptom and function deterioration defined as a change (\>= 10 points on a 0-100 scale) in fatigue, physical functioning, cognitive functioning, or role functioning as measured by the Fatigue, Physical, Cognitive, Role Functioning scales of the EORTC QLQ-C30.
| Months | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Physical Functioning | NA (0.99 to NA) | 11.56 (5.55 to NA) |
| Cognitive Functioning | 11.99 (1.91 to NA) | 8.25 (5.55 to NA) |
| Role Functioning | 2.83 (1.35 to 6.47) | 4.07 (1.61 to 6.47) |
| Fatigue | 1.35 (0.95 to NA) | 1.45 (1.38 to 6.47) |
Duration of Stable/Improved HRQoL scores as assessed through use of the two-item Global Health Status (GHS)/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30.
| Months | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib |
|---|---|---|
| Duration of Stable/Improved Health-related Quality of Life (HRQoL) Scores | NA (15.21 to NA) | 6.14 (3.68 to 10.32) |
The safety profile of Cobimetinib plus Atezolizumab and Cobimetinib plus Atezolizumab plus Vemurafenib is evaluated in terms of occurrence and severity of AEs. Severity will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0)
| Participants | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Cohort 2 - Cobimetinib and Vemurafenib |
|---|---|---|---|
| Occurrence | 15 | 60 | 5 |
| Grade 1 | 1 | 1 | 0 |
| Grade 2 | 3 | 13 | 1 |
| Grade 3 | 9 | 35 | 2 |
| Grade 4 | 1 | 10 | 0 |
| Grade 5 | 1 | 1 | 2 |
Collected over Baseline up to 4 years, 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1- Cobimetinib and Atezolizumab | 11/15 (73.3%) | 6/15 (40%) | 15/15 (100%) |
| Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | 47/60 (78.3%) | 21/60 (35%) | 60/60 (100%) |
| Cohort 2 - Cobimetinib and Vemurafenib | 3/5 (60%) | 5/5 (100%) | 4/5 (80%) |
| Event | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Cohort 2 - Cobimetinib and Vemurafenib |
|---|---|---|---|
| Gallbladder ruptureHepatobiliary disorders | 0/15 | 0/60 | 1/5 |
| Septic shockInfections and infestations | 0/15 | 0/60 | 1/5 |
| Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders | 0/15 | 0/60 | 1/5 |
| RashSkin and subcutaneous tissue disorders | 0/15 | 1/60 | 1/5 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/15 | 0/60 | 1/5 |
| Cardiac failureCardiac disorders | 1/15 | 0/60 | 0/5 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/15 | 0/60 | 0/5 |
| DeathGeneral disorders | 1/15 | 0/60 | 0/5 |
| Influenza like illnessGeneral disorders | 1/15 | 0/60 | 0/5 |
| Hepatitis toxicHepatobiliary disorders | 1/15 | 0/60 | 0/5 |
| Event | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Cohort 2 - Cobimetinib and Vemurafenib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/15 | 29/60 | 0/5 |
| Blood creatine phosphokinase increasedInvestigations | 2/15 | 28/60 | 0/5 |
| PyrexiaGeneral disorders | 3/15 | 26/60 | 1/5 |
| Lipase increasedInvestigations | 0/15 | 23/60 | 0/5 |
| RashSkin and subcutaneous tissue disorders | 1/15 | 20/60 | 0/5 |
| AstheniaGeneral disorders | 4/15 | 19/60 | 0/5 |
| Amylase increasedInvestigations | 0/15 | 19/60 | 0/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/15 | 19/60 | 1/5 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 4/15 | 18/60 | 0/5 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 2/15 | 17/60 | 1/5 |
| Age, Continuous(Years) | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Total |
|---|---|---|---|
| Mean | 60.9 ± 12.5 | 54.4 ± 13.9 | 55.6 ± 13.8 |
| Sex: Female, Male(Participants) | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Total |
|---|---|---|---|
| Female | 9 | 24 | 33 |
| Male | 6 | 41 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 9 | 9 |
| Not Hispanic or Latino | 11 | 50 | 61 |
| Unknown or Not Reported | 4 | 6 | 10 |
| Race (NIH/OMB)(Participants) | Cohort 1- Cobimetinib and Atezolizumab | Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 11 | 61 | 72 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Jun 2021, 29 months.
Results were first posted in Feb 2024, 2 years 8 months after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 29 months is below that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cobimetinib · Atezolizumab